# A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

> **NCT05851924** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** NALIRIFOX
- **COMBINATION_PRODUCT:** AD-XRT and Capecitabine

## Key facts

- **NCT ID:** NCT05851924
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-12
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05851924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05851924, "A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05851924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*